Home/Filings/4/0001410939-23-000060
4//SEC Filing

Carroll David Francis 4

Accession 0001410939-23-000060

CIK 0001410939other

Filed

May 2, 8:00 PM ET

Accepted

May 3, 5:31 PM ET

Size

9.1 KB

Accession

0001410939-23-000060

Insider Transaction Report

Form 4
Period: 2023-05-01
Carroll David Francis
SVP, CFO and Treasurer
Transactions
  • Exercise/Conversion

    Common Stock

    2023-05-01$2.81/sh+63,500$178,435131,972 total
  • Sale

    Common Stock

    2023-05-01$37.04/sh63,500$2,352,04068,472 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2023-05-01$2.81/sh63,500$178,4350 total
    Exercise: $2.81Exp: 2027-04-23Common Stock (63,500 underlying)
Footnotes (3)
  • [F1]The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2022.
  • [F2]The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $36.75 to 37.51 per share on May 1, 2023. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
  • [F3]This stock option award was granted on April 24, 2017 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date.

Issuer

IVERIC bio, Inc.

CIK 0001410939

Entity typeother

Related Parties

1
  • filerCIK 0001703623

Filing Metadata

Form type
4
Filed
May 2, 8:00 PM ET
Accepted
May 3, 5:31 PM ET
Size
9.1 KB